Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer

Trial Profile

Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Paclitaxel
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Status changed from active, no longer recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top